Widespread distribution of nirsevimab to infants with respiratory syncytial virus infection raised concerns about potential ...

It’s time for the provincial government to stop dragging its heels on paying for a pair of injections that can protect the ...

As infection rates of illnesses carried by mosquitoes increase, companies and researchers are racing to develop effective ...

Infants are among the most susceptible to respiratory complications from respiratory syncytial virus, or RSV. While they can ...

Recruitment is underway for a clinical trial testing a vaccine candidate produced with The University of Queensland's molecular clamp technology against life-threatening respiratory viruses.

Here's what experts say about using antibiotics to treat the common cold — and why you can still catch one in the summer.

Vicebio, the vaccine company licensed to develop the UQ technology, has developed a new candidate vaccine to fight respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Both viruses ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)—which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

Health Canada's approval is based on data from the Phase 3 clinical trial ConquerRSV, a global study conducted in approximately 37,000 adults aged 60 years and older in 22 countries. No serious safety ...

A viral outbreak in Kolkata is causing dengue-like symptoms including high fever, joint pain, and rashes. Despite extensive testing, few patients are testing positive for dengue or malaria, leading ...